Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

Libtayo was first approved in 2018, several years after Bristol-Myers Squibb and Merck & Co began to gain market share in many oncology indications with their rival PD-1 drugs Opdivo (nivolumab ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

In January 2025, BioWorld tracked 171 phase I-III clinical trial updates, down from 212 in December. The month delivered 12 successful phase III outcomes, six of those in cancer, while two trials ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy ...